The Effect of Oral Baclofen and Botulinum Toxin Treatments in Hemiplegic Spasticity on the Nociceptive Flexor Reflex
Stroke Sequelae, Spastic Hemiplegia
About this trial
This is an interventional treatment trial for Stroke Sequelae focused on measuring Antispastic drugs, Nociceptive flexor reflex, Baclofen, Botulinum toxin
Eligibility Criteria
Inclusion Criteria:
- Being between the ages of 18-60
- To accept voluntary participation in the study
- Spastic Hemiplegia (Modified Ashworth Scale 2 and above)
Exclusion Criteria:
- Pregnant women, breastfeeding and younger than 18 years
- To have medication and substance use causing neuropathy in the history of the disease and / or neuropathy
- Companies that have received botulinum toxin injection therapy and / or oral antispastic therapy within the last 6 months
- Have a history of allergies and hypersensitivity to usability drug
- Injection treatment planned purification hematoma, cleaning or skin lesion to be
Sites / Locations
- Hatay Mustafa Kemal University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Other
Spastic hemiplegia , Botox
Spastic hemiplegia, Baclofen
Botulinum toxin (BTX), being one of the most potent biological toxins, acts by blocking neuromuscular transmission via inhibiting acetylcholine release. Currently, focal spasticity is being treated successfully with BTX via injecting in the spastic muscles( Dose: 300-400 iu). Two antigenically distinct serotypes of BTX are available on the market as type A and B.
Baclofen is an agonist that has presynaptic and postsynaptic effects on monosynaptic and polysynaptic pathways by binding to GABA B receptors. The recommended dosing regimen is initiated with 5 mg 3 times a day. It can be increased by 15-mg/d increments at 3-day intervals as needed. Dosing should not exceed 80 mg/d.